SLC5A2 and type 2 diabetes mellitus: Increasing meta-analyses (Sattar et al., 2021d; McGuire et al., 2021; Ali et al., 2022) based on the cardiovascular outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) have confirmed the cardiovascular and renal benefits of these two drug classes among patients with type 2 diabetes (T2D) and/or cardiorenal disease.